Quy Nguyen

Dr. Quy Nguyen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PSPeng Sun
Peng Sun
RVRemy Vu
Remy Vu
MDMorgan Dragan
Morgan Dragan
DHDaniel Haensel
Daniel Haensel
GGGuadalupe Gutierrez
Guadalupe Gutierrez
XDXing Dai
Xing Dai

15 April 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GQGuangrong Qin
Guangrong Qin
JDJin Dai
Jin Dai
SCSylvia Chien
Sylvia Chien
TMTimothy J. Martins
Timothy J. Martins
BLBrenda Loera
Brenda Loera
PBPamela S. Becker
Pamela S. Becker
Purpose: The inherent genetic heterogeneity of acute myeloid leukemia (AML) has challenged the development of precise and effective therapies. The objective of this study was to elucidate the genomic basis of drug resistance or sensitivity, identify signatures for drug response prediction, and provide resources to the research community. Experimental Design: We performed targeted sequencing, high-throughput drug screening, and single-cell genomic profiling on leukemia cell samples derived from patients with AML. Statistical approaches and machine learning models were applied to identify signatures for drug response prediction. We also integrated large public datasets to understand the co-occurring mutation patterns and further investigated the mutation profiles in the single cells. The features revealed in the co-occurring or mutual exclusivity pattern were further subjected to machine learning models. Results: We detected genetic signatures associated with sensitivity or resistance to specific agents, and identified five co-occurring mutation groups. The application of single-cell genomic sequencing unveiled the co-occurrence of variants at the individual cell level, highlighting the presence of distinct subclones within patients with AML. Using the mutation pattern for drug response prediction demonstrates high accuracy in predicting sensitivity to some drug classes, such as MEK inhibitors for RAS-mutated leukemia. Conclusions: Our study highlights the importance of considering the gene mutation patterns for the prediction of drug response in AML. It provides a framework for categorizing patients with AML by mutations that enable drug sensitivity prediction.

23 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BDBhaba Das
Bhaba Das
AKAarthi Kannan
Aarthi Kannan
QNQuy Nguyen
Quy Nguyen
JGJyoti Gogoi
Jyoti Gogoi
HZHaibo Zhao
Haibo Zhao
LGLing Gao
Ling Gao
Merkel cell carcinoma (MCC) is an often-lethal skin cancer with increasing incidence and limited treatment options. Although immune checkpoint inhibitors (ICI) have become the standard of care in advanced MCC, 50% of all MCC patients are ineligible for ICIs, and amongst those treated, many patients develop resistance. There is no therapeutic alternative for these patients, highlighting the urgent clinical need for alternative therapeutic strategies. Using patient-derived genetic insights and data generated in our lab, we identified aurora kinase as a promising therapeutic target for MCC. In this study, we examined the efficacy of the recently developed and highly selective AURKA inhibitor, AK-01 (LY3295668), in six patient-derived MCC cell lines and two MCC cell-line-derived xenograft mouse models. We found that AK-01 potently suppresses MCC survival through apoptosis and cell cycle arrest, particularly in MCPyV-negative MCC cells without RB expression. Despite the challenge posed by its short in vivo durability upon discontinuation, the swift and substantial tumor suppression with low toxicity makes AK-01 a strong potential candidate for MCC management, particularly in combination with existing regimens.

5 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SHStephanie Hachey
Stephanie Hachey
SMSilva Movsesyan
Silva Movsesyan
QNQuy Nguyen
Quy Nguyen
GBGiselle Burton-Sojo
Giselle Burton-Sojo
ATAni Tankanzyan
Ani Tankanzyan
CHChristopher C.W. Hughes
Christopher C.W. Hughes
Around 95% of anti-cancer drugs that show promise during preclinical study fail to gain FDA-approval for clinical use. This failure of the preclinical pipeline highlights the need for improved, physiologically-relevant in vitro models that can better serve as reliable drug-screening tools. The vascularized micro-tumor (VMT) is a novel three-dimensional model system that recapitulates the complex human tumor microenvironment, including perfused vasculature, within a transparent microfluidic device, allowing real-time study of drug responses and tumor-stromal interactions. Here we have validated the VMT platform for the study of colorectal cancer (CRC), the second leading cause of cancer-related deaths, by showing that gene expression, tumor heterogeneity, and treatment response in the VMT more closely model CRC tumor clinicopathology than current standard drug screening modalities, including 2-dimensional (2D) monolayer culture and 3-dimensional (3D) spheroids.

14 June 2024
Verified
Other
Open access
GQGuangrong Qin
Guangrong Qin
JDJin Dai
Jin Dai
SCSylvia Chien
Sylvia Chien
TMTimothy J. Martins
Timothy J. Martins
BLBrenda Loera
Brenda Loera
PBPamela S. Becker
Pamela S. Becker
Purpose:The inherent genetic heterogeneity of acute myeloid leukemia (AML) has challenged the development of precise and effective therapies. The objective of this study was to elucidate the genomic basis of drug resistance or sensitivity, identify signatures for drug response prediction, and provide resources to the research community.Experimental Design:We performed targeted sequencing, high-throughput drug screening, and single-cell genomic profiling on leukemia cell samples derived from patients with AML. Statistical approaches and machine learning models were applied to identify signatures for drug response prediction. We also integrated large public datasets to understand the co-occurring mutation patterns and further investigated the mutation profiles in the single cells. The features revealed in the co-occurring or mutual exclusivity pattern were further subjected to machine learning models.Results:We detected genetic signatures associated with sensitivity or resistance to specific agents, and identified five co-occurring mutation groups. The application of single-cell genomic sequencing unveiled the co-occurrence of variants at the individual cell level, highlighting the presence of distinct subclones within patients with AML. Using the mutation pattern for drug response prediction demonstrates high accuracy in predicting sensitivity to some drug classes, such as MEK inhibitors for RAS-mutated leukemia.Conclusions:Our study highlights the importance of considering the gene mutation patterns for the prediction of drug response in AML. It provides a framework for categorizing patients with AML by mutations that enable drug sensitivity prediction.